82
Participants
Start Date
May 16, 2013
Primary Completion Date
August 27, 2021
Study Completion Date
September 27, 2021
Total Lymphoid Irradiation
Participants receive total lymphoid irradiation over four doses.
Fludarabine
Given IV.
Cyclophosphamide
Given IV.
Thiotepa
Given IV.
Melphalan
Given IV.
HPC,A Infusion
Participants received infusions of HPC,A (CD34+ selected) and HPC,A (CD45RA depleted).
TC-NK Infusion
Participants receive infusions of TC-NK.
G-CSF
"Participants receive G-CSF subcutaneously or intravenously.~Donors receive G-CSF subcutaneously during cell mobilization."
Mesna
Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
CliniMACS
The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
Mycophenolate mofetil
Given intravenously or orally.
St. Jude Children's Research Hospital, Memphis
Assisi Foundation
OTHER
St. Jude Children's Research Hospital
OTHER